MOLN - Molecular Partners AG Stock Price and Quote

MOLN [NASD]

Healthcare | Biotechnology | Switzerland

Index	-	P/E	1.57	EPS (ttm)	3.86	Insider Own	-	Shs Outstand	32.53M	Perf Week	1.65%
Market Cap	209.70M	Forward P/E	-	EPS next Y	-2.02	Insider Trans	-	Shs Float	18.68M	Perf Month	0.10%
Income	128.60M	PEG	-	EPS next Q	-	Inst Own	3.00%	Short Float / Ratio	0.08% / 6.43	Perf Quarter	-7.82%
Sales	206.90M	P/S	1.01	EPS this Y	276.40%	Inst Trans	-1.04%	Short Interest	0.02M	Perf Half Y	-3.22%
Book/sh	7.89	P/B	0.77	EPS next Y	-154.00%	ROA	-	Target Price	14.33	Perf Year	-70.37%
Cash/sh	7.83	P/C	0.77	EPS next 5Y	-	ROE	-	52W Range	5.50 - 21.80	Perf YTD	-7.82%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	48.60%	52W High	-72.30%	Beta	-
Dividend %	-	Quick Ratio	14.80	Sales past 5Y	-	Gross Margin	-	52W Low	9.78%	ATR	0.19
Employees	175	Current Ratio	14.80	Sales Q/Q	-3.80%	Oper. Margin	-	RSI (14)	47.81	Volatility	0.38% 2.61%
Optionable	No	Debt/Eq	0.02	EPS Q/Q	-1.10%	Profit Margin	-	Rel Volume	0.12	Prev Close	6.00
Shortable	Yes	LT Debt/Eq	0.02	Earnings	Mar 09 AMC	Payout	0.00%	Avg Volume	2.43K	Price	6.04
Recom	2.70	SMA20	-0.11%	SMA50	-5.48%	SMA200	-7.10%	Volume	286	Change	0.63%

Aug-30-22

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

Aug-29-22

Downgrade

SVB Leerink

Outperform → Mkt Perform

$30 → $8

May-25-22

Upgrade

Credit Suisse

Underperform → Neutral

Apr-27-22

Downgrade

Credit Suisse

Neutral → Underperform

Jul-13-21

Initiated

Cowen

Outperform

$50

Jul-12-21

Resumed

SVB Leerink

Outperform

$36

Mar-13-23 09:30AM	Molecular Partners Publishes Invitation to Annual General Meeting 2023 GlobeNewswire +9.04%
12:22AM	Molecular Partners AG (NASDAQ:MOLN) Q4 2022 Earnings Call Transcript Insider Monkey
Mar-11-23 02:14AM	Molecular Partners Full Year 2022 Earnings: Beats Expectations Simply Wall St.
Mar-09-23 04:00PM	Molecular Partners Reports Corporate Highlights From Q4 2022 and Key Financials for Full Year 2022 GlobeNewswire -5.31%
Mar-02-23 04:00PM	Molecular Partners to Hold Conference Call to Discuss Fourth Quarter and Full Year 2022 Results and Present at the 43rd Annual Cowen Health Care Conference GlobeNewswire
01:15AM	Loading…
Feb-28-23 01:15AM	Molecular Partners Presents New Preclinical Data Supporting Its Radio DARPin Therapy Platform GlobeNewswire
Feb-10-23 01:00AM	Molecular Partners to Present at SVB Leerink Global Healthcare Conference GlobeNewswire
Jan-16-23 01:00AM	Molecular Partners Initiates Clinical Study of Trispecific Candidate MP0533 for the Treatment of Acute Myeloid Leukemia GlobeNewswire
Jan-12-23 06:18AM	Hedge funds own 28% of Molecular Partners AG (VTX:MOLN) shares but individual investors control 41% of the company Simply Wall St.
Jan-08-23 03:00PM	Molecular Partners Provides Updates at 41st Annual JPM Healthcare Conference GlobeNewswire
Dec-30-22 01:00AM	Molecular Partners to Present at 41st Annual JP Morgan Healthcare Conference and Swiss Investor Conferences GlobeNewswire +6.16%
Dec-12-22 07:00PM	Molecular Partners Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML GlobeNewswire
Dec-01-22 11:46PM	Molecular Partners AG's (VTX:MOLN) Stock's On An Uptrend: Are Strong Financials Guiding The Market? Simply Wall St. +10.62%
Nov-10-22 01:00AM	Molecular Partners Presents Positive Interim Safety and Mechanistic Data From Ongoing Phase 1 Trial of MP0317 for Treatment of Solid Tumors GlobeNewswire
Nov-04-22 09:39AM	Investors in Molecular Partners (VTX:MOLN) have unfortunately lost 77% over the last five years Simply Wall St.
12:30PM	Loading…
Nov-03-22 12:30PM	Molecular Partners Announces Acceptance of Oral Presentation at the Annual American Society of Hematology Meeting GlobeNewswire
Nov-02-22 12:30PM	Molecular Partners Announces Upcoming Participation in Investor and Scientific Conferences GlobeNewswire
Oct-27-22 04:00PM	Molecular Partners Announces Planned Departure of Chief Financial Officer GlobeNewswire
04:00PM	Interim Management Statement Q3 2022: Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated by Year-End GlobeNewswire
Aug-25-22 04:30PM	Molecular Partners Reports Corporate Highlights and H1 2022 Financials GlobeNewswire +10.16%
Aug-18-22 01:00AM	Molecular Partners Half Year 2022 News Release and Investor Call Details GlobeNewswire
Jul-21-22 11:30AM	Molecular Partners Announces Publication in Nature Biotechnology Detailing Design and Mechanism of Ensovibep DARPin Antiviral for SARS-CoV-2 GlobeNewswire
Jun-10-22 01:00AM	Molecular Partners Announces Participation in Scientific Conferences GlobeNewswire
May-12-22 04:05PM	Interim Management Statement Q1 2022 of Molecular Partners: Cash Runway into 2026 and Portfolio Progress Highlight Strategic Momentum GlobeNewswire
May-11-22 01:00AM	Molecular Partners to Participate in Upcoming Healthcare Investor Conferences GlobeNewswire
May-03-22 12:00PM	Molecular Partners CEO, Patrick Amstutz, Elected President of the Swiss Biotech Association GlobeNewswire
Apr-27-22 08:02AM	Molecular Partners shares tumble 37% after Amgen returns rights to tumor treatment candidate MarketWatch -37.37%
06:01AM	Molecular Partners Regains Rights To Early-Stage Cancer Asset From Amgen Benzinga
05:59AM	Molecular Partners, Novartis Note EUA For COVID-19 Therapy May Need Additional Data Benzinga
Apr-26-22 04:05PM	Molecular Partners to Regain Global Rights for MP0310 from Amgen GlobeNewswire -16.17%
02:00PM	Loading…
02:00PM	Molecular Partners Provides Update on Ensovibep Following Novartis Quarterly Earnings Call GlobeNewswire
Apr-23-22 01:00AM	Molecular Partners Announces Presentation of the EMPATHY Study of Ensovibep for the Treatment of COVID-19 at ECCMID 2022 GlobeNewswire
Apr-13-22 12:00PM	Molecular Partners to Present at Kempen Life Sciences Investor Conference GlobeNewswire
09:00AM	Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General Meeting GlobeNewswire
Mar-24-22 02:00AM	Molecular Partners Announces Publication of Preclinical Data from CD40 Therapeutic Candidate MP0317 in Cancer Immunology Research GlobeNewswire
Mar-17-22 01:00AM	Molecular Partners Publishes Invitation to Annual General Meeting 2022 GlobeNewswire
Mar-15-22 04:30PM	Molecular Partners Reports Corporate Highlights From Q4 2021 and Key Financials for Full Year 2021 GlobeNewswire -9.17%
Feb-25-22 04:30PM	Molecular Partners to Present at Upcoming Healthcare Investor Conferences GlobeNewswire
Feb-11-22 04:10PM	Molecular Partners to Present at Upcoming Healthcare Investor Conference GlobeNewswire
Feb-10-22 07:13AM	Molecular Partners, Novartis Submit Emergency Use Authorization Request For Ensovibep For COVID-19 Benzinga
01:00AM	Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration for the Treatment of COVID-19 GlobeNewswire
Jan-28-22 05:57AM	3 Stocks That Have Soared as the Market Sank: Are They Buys Now? Motley Fool
Jan-23-22 02:28AM	Novartis Hopes to Have Another COVID Therapy on the Way Motley Fool
Jan-18-22 01:00AM	Molecular Partners Finalizes License Agreement with Novartis for Ensovibep for COVID-19 GlobeNewswire -16.90%
Jan-13-22 05:00PM	Molecular Partners Reports Disclosure of Major Shareholder as per Swiss Stock Exchange Regulations GlobeNewswire
Jan-12-22 10:13AM	Biotech Stock Roundup: BIIB's AD Drug Update, AMGN's Drug Approval & Other Updates Zacks +5.53%
Jan-11-22 11:37AM	Molecular (MOLN), Novartis Post Positive Data From COVID-19 Drug Zacks +19.44%
Jan-10-22 06:51PM	Why Molecular Partners Stock Crushed the Market Today Motley Fool +30.22%
09:32AM	Molecular Partners Stock Surges as Novartis Plans to License Covid-19 Drug Barrons.com
08:58AM	European stocks led lower by techs, on rate concerns and Atos warning MarketWatch
07:31AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday InvestorPlace
07:13AM	Novartis-Molecular Partners COVID drug could be on market in weeks Reuters
06:00AM	Molecular Partners Stock Surges as Novartis Plans to License Covid-19 Drug Barrons.com
05:46AM	Novartis To In-License COVID-19 Treatment From Molecular Partners, After Encouraging Mid-Stage Data Benzinga
03:35AM	Novartis to seek FDA approval for COVID-19 treatment after positive data MarketWatch
01:17AM	Molecular Partners and Novartis Report Positive Topline Data from Phase 2 Study for Ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19 GlobeNewswire
Jan-06-22 10:00AM	Wall Street Analysts See a 96% Upside in Molecular Partners AG Sponsored ADR (MOLN): Can the Stock Really Move This High? Zacks
Jan-05-22 04:05PM	Molecular Partners to Present at Upcoming Healthcare Investor Conferences GlobeNewswire -5.38%
Dec-15-21 01:00AM	Molecular Partners to Host Oncology Day (Virtual) GlobeNewswire
Dec-14-21 12:16PM	Molecular Partners Inks License Deal With Novartis For $580M Benzinga +10.21%
01:00AM	Molecular Partners Announces Collaboration with Novartis to Develop DARPin-Conjugated Radioligand Therapeutic Candidates for Oncology GlobeNewswire
Dec-12-21 04:00PM	Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical Studies GlobeNewswire
Dec-09-21 01:00AM	Molecular Partners Highlights Upcoming Oncology Portfolio Presentations in December GlobeNewswire
Dec-06-21 01:00AM	Molecular Partners Presents Results from a Phase 2a Trial of Ensovibep in 12 COVID-19 Patients at ESWI 2021 GlobeNewswire
Dec-03-21 01:00AM	Molecular Partners Announces Research Collaboration with University of Bern to Develop MP0533, a Multispecific DARPin for the Treatment of AML GlobeNewswire
Nov-30-21 12:48PM	These 2 Nasdaq Biotechs Are Bucking the Market Downtrend Motley Fool +19.44%
01:00AM	Molecular Partners Confirms Retained Activity of Ensovibep on the Positions Mutated in Emerging Omicron Variant of SARS-CoV-2 In Vitro GlobeNewswire
Nov-24-21 01:00AM	Molecular Partners Announces Presentation at the Evercore ISI 4th Annual HealthCONx Conference GlobeNewswire -5.23%
Nov-16-21 06:49AM	36 Stocks Moving in Tuesday's Pre-Market Session Benzinga -31.37%
05:51AM	See Why Molecular Partners Shares Dropped To 52-Week Low During Tuesday Premarket? Benzinga
01:00AM	Molecular Partners Provides Update from ACTIV-3 Global Clinical Study of Ensovibep in Patients Hospitalized with COVID-19 GlobeNewswire
Nov-04-21 02:00AM	Molecular Partners Announces First Patient Dosed with CD40 Therapeutic Candidate MP0317 in Phase 1 Clinical Trial GlobeNewswire
Oct-28-21 01:00AM	Interim Management Statement Q3 2021 of Molecular Partners: Advancement of COVID-19 Clinical Program and Continued Immuno-Oncology Momentum GlobeNewswire
Oct-20-21 01:00AM	Molecular Partners Present Data Demonstrating Successful Inhibition of COVID19 Viral Variants with Ensovibep at the 2021 ISIRV-WHO Conference GlobeNewswire
Sep-03-21 04:05PM	Molecular Partners to Present at Upcoming Healthcare Investor Conferences GlobeNewswire
Aug-26-21 01:00AM	Molecular Partners Reports Corporate Highlights and Key Financials for H1 2021 GlobeNewswire
Aug-09-21 01:00AM	Molecular Partners to Regain Global Rights to Abicipar GlobeNewswire
Jul-13-21 06:55AM	Cowen Initiates Coverage On Molecular Partners With Price Target Of $50 Benzinga
Jul-08-21 09:04AM	Molecular Partners - Novartis' COVID-19 Antiviral Shows Encouraging Preclinical Action Against Delta Variant Benzinga
08:30AM	Molecular Partners Shares Development in Ensovibep Program SmarterAnalyst
01:00AM	Molecular Partners Reports Continued Progress of Ensovibep Global Clinical Program; Positive in vitro Data Demonstrating Maintained Inhibition of Delta and All Other Known Variants of Concern of SARS-CoV-2 GlobeNewswire
Jun-15-21 10:00PM	Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States ACCESSWIRE
Jun-13-21 04:00PM	Molecular Partners Announces First Patient Dosed in COVID-19 NIH-Sponsored ACTIV-3 Trial Evaluating Antiviral Candidate Ensovibep ACCESSWIRE

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience